Physician profile
Gavin Setzen
NPI 1063419232
$243,353.49
in general payments reported to CMS, 2019-2025
35 companies · $70K in 2025
The $70K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $8,730 · 2021: $1,691 · 2022: $65K · 2023: $2,651 · 2024: $67K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $126K · Travel and Lodging: $6,354 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,750 · Food and Beverage: $2,486 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $126,210.00 |
| Travel and Lodging | $6,353.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,750.00 |
| Food and Beverage | $2,485.60 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $143,398.07 | 2019-2025 | Scopis Ent, Na, Latera |
| Aerin Medical INC. | $69,979.53 | 2024-2025 | |
| Smith+Nephew, INC. | $13,511.35 | 2019-2025 | Tula |
| Neurent Medical Limited | $8,130.08 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Lilly USA, LLC | $3,750.00 | 2025 | Zepbound |
| Intersect Ent, INC. | $529.45 | 2019-2021 | |
| Glaxosmithkline, LLC. | $424.82 | 2019-2025 | Nucala, Trelegy Ellipta |
| Optinose US, INC. | $392.63 | 2019-2025 | |
| Genzyme Corporation | $385.46 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $376.71 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $366.77 | 2019-2025 | Dupixent |
| Acclarent, INC | $345.78 | 2019 | |
| Csl Behring | $221.09 | 2020-2025 | Hizentra, Haegarda |
| Astrazeneca Pharmaceuticals Lp | $215.32 | 2019-2022 | |
| Harmony Biosciences LLC | $191.48 | 2020-2024 | Wakix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $130.70 | 2019-2022 | |
| Pharming Healthcare, INC. | $124.13 | 2022-2025 | Ruconest |
| Amgen INC. | $121.84 | 2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $103.42 | 2019-2021 | |
| Grifols USA, LLC | $100.68 | 2019-2023 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $91.15 | 2022-2025 | Cuvitru |
| Kaleo, INC. | $81.42 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $71.02 | 2019 | |
| Aimmune Therapeutics, INC. | $46.22 | 2021 | |
| Medtronic USA, INC. | $41.75 | 2019 | |
| Greer Laboratories, INC. | $39.06 | 2019 | |
| Ethicon US, LLC | $35.37 | 2019 | |
| Shire North American Group INC | $29.21 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $27.91 | 2024 | Lumryz |
| Axsome Therapeutics, INC. | $25.53 | 2022 | |
| Phathom Pharmaceuticals, INC. | $22.96 | 2025 | Voquezna |
| Hikma Pharmaceuticals USA | $16.21 | 2023 | Ryaltris |
| Arbor Pharmaceuticals, INC. | $13.36 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.01 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavin Setzen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.